Transcripta Bio x Synfini: Huntington's disease lead compound in weeks, versus an industry average of 12-18 months

## Transcripta Bio x Synfini: a Huntington's disease lead compound in weeks AI drug discovery company Transcripta Bio and the "AI chemistry foundry" Synfini have announced the results of their collaboration: against the MSH3 gene, they obtained a validation-grade lead compound within weeks, whereas the industry benchmark from hit compound to candidate nomination is 12-18 months. **Key points** - **The target**: MSH3 is believed to drive the "somatic repeat expansion" in Huntington's disease, and the speed of repeat expansion determines how fast the disease progresses. Huntington's disease affects about 41,000 patients in the US, with more than 200,000 others at genetic risk; the causative gene was found in 1993, and in 33 years there is still no approved therapy that can alter the course of the disease, only symptomatic treatment. - **The approach**: Transcriptome-scale target biology (Transcripta Bio) plus AI-driven automated chemistry (Synfini) compress the discovery and chemistry cycles to a fraction of the usual time. - **Significance**: In one of the hardest areas of drug development, targeting a disease with no available treatment, the speed advantage of AI drug discovery is beginning to pay off: speed itself has become pipeline value. > Source: [read the original](https://www.businesswire.com/news/home/20261007783241/en/Transcripta-Bio-Synfini-Collaborate-to-Identify-a-Lead-Candidate-Against-a-Key-Driver-of-Huntingtons-Disease-Progression-in-a-Matter-of-Weeks). This text is a summary for reference only.